Genotype II Live-Attenuated ASFV Vaccine Strains Unable to Completely Protect Pigs against the Emerging Recombinant ASFV Genotype I/II Strain in Vietnam
Nguyen Van Diep, Nguyen Van Duc, Nguyen Thi Hong Ngọc, Xuan Dang Vu, Tran Ngoc Tiep, Việt Dũng Nguyễn, Thi Tam Than, Dustin Maydaniuk, Kalhari Goonewardene, Aruna Ambagala, Van Phan Le
Abstract
Background: African swine fever virus (ASFV) continues to spread globally, causing severe economic losses to pig farmers. Vietnam licensed two live attenuated vaccines based on the ASFV strains ASFV-G-ΔI177L and ASFV-G-ΔMGF to control the ongoing ASF outbreaks. In 2023, newly emerging highly virulent recombinant ASF viruses (rASFV I/II) containing genetic elements from both p72 genotype I and II ASF viruses were reported from Northern Vietnam. Objective: This study evaluated whether the two vaccine strains were able to protect the pigs against the emerging rASFV I/II strain VNUA/rASFV/TN1/23. Results: Pigs vaccinated with ASFV-G-ΔMGF or ASFV-G-ΔI177L, when challenged with rASFV I/II, succumbed to the infection, or developed signs of chronic ASF. Conclusions: The findings from this study show that both vaccine strains that are licensed and used in Vietnam are unlikely to protect pigs from the emerging highly virulent rASFV I/II. This complicates the ongoing efforts to control ASF in Asia and globally and emphasizes the urgent need for a novel vaccine that can effectively protect pigs from the rASFV I/II.